A novel glutaminase inhibitor-968 inhibits the migration and proliferation of non-small cell lung cancer cells by targeting EGFR/ERK signaling pathway

Oncotarget

Volumn 8, Issue 17, 2017, Pages 28063-28073

  Han, Tianyu ^a   Guo, Meng ^a   Zhang, Tingting ^b   Gan, Mingxi ^a   Xie, Caifeng ^a   Wang, Jian Bin ^a  

^a NANCHANG UNIVERSITY   (China)

^b SHANXI UNIVERSITY   (China)

Author keywords

Autophagy; Epidermal growth factor receptor; Glutaminase inhibitor; Glutamine metabolism; Non small cell lung cancer

Indexed keywords

5 [3 BROMO 4 (DIMETHYLAMINO)PHENYL] 2,2 DIMETHYL 2,3,5,6 TETRAHYDROBENZ[A]PHENANTHRIDIN 4(1H) ONE; CHLOROQUINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTAMINASE; GLUTAMINASE C; HYDROLASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; UNCLASSIFIED DRUG; BECLIN 1; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; CELL CYCLE; CELL CYCLE CHECKPOINT; CELL MOTION; DRUG EFFECT; LUNG TUMOR; METABOLISM; TUMOR CELL LINE;

AUTOPHAGY; BECLIN-1; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENZYME INHIBITORS; ERBB RECEPTORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLUTAMINASE; HUMANS; LUNG NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85018392260     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.14188     Document Type: Article

References (28)

1. Warburg O. On the origin of cancer cells. Science. 1956; 123:309-314
2. Eagle H. Nutrition needs of mammalian cells in tissue culture. Science. 1955; 122:501-514
3. Kvamme E and Svenneby G. Effect of anaerobiosis and addition of keto acids on glutamine utilization by Ehrlich ascites-tumor cells. Biochimica et biophysica acta. 1960; 42:187-188
4. Deberardinis RJ, Sayed N, Ditsworth D and Thompson CB. Brick by brick: metabolism and tumor cell growth. Current opinion in genetics & development. 2008; 18:54-61
5. Aledo JC, Gomez-Fabre PM, Olalla L and Marquez J. Identification of two human glutaminase loci and tissuespecific expression of the two related genes. Mammalian genome. 2000; 11:1107-1110
6. Curthoys NP, Kuhlenschmidt T, Godfrey SS and Weiss RF. Phosphate-dependent glutaminase from rat kidney. Cause of increased activity in response to acidosis and identity with glutaminase from other tissues. Archives of biochemistry and biophysics. 1976; 172:162-167
7. Elgadi KM, Meguid RA, Qian M, Souba WW and Abcouwer SF. Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiological genomics. 1999; 1:51-62
8. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT and Dang CV. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009; 458:762-765
9. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, Wilson KF, Ambrosio AL, Dias SM, Dang CV and Cerione RA. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer cell. 2010; 18:207-219
10. van den Heuvel AP, Jing J, Wooster RF and Bachman KE. Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth. Cancer biology & therapy. 2012; 13:1185-1194
11. Yu D, Shi X, Meng G, Chen J, Yan C, Jiang Y, Wei J and Ding Y. Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma. Oncotarget. 2015; 6:7619-7631. doi: 10.18632/oncotarget.3196
12. Chen Z, Wang JN, Ma GX and Zhang YS. China tackles the health effects of air pollution. Lancet. 2013; 382:1959-1960
13. Devesa SS, Bray F, Vizcaino AP and Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. International journal of cancer Journal international du cancer. 2005; 117:294-299
14. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C, Wilson C, Myer VE, MacKeigan JP, Porter JA, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009; 136:521-534
15. Kandil HM, Argenzio RA, Chen W, Berschneider HM, Stiles AD, Westwick JK, Rippe RA, Brenner DA and Rhoads JM. L-glutamine and L-asparagine stimulate ODC activity and proliferation in a porcine jejunal enterocyte line. The American journal of physiology. 1995; 269:G591-599
16. Rhoads JM, Argenzio RA, Chen W, Rippe RA, Westwick JK, Cox AD, Berschneider HM and Brenner DA. L-glutamine stimulates intestinal cell proliferation and activates mitogen-activated protein kinases. The American journal of physiology. 1997; 272:G943-953
17. Catane R, Von Hoff DD, Glaubiger DL and Muggia FM. Azaserine, DON, and azotomycin: three diazo analogs of L-glutamine with clinical antitumor activity. Cancer treatment reports. 1979; 63:1033-1038
18. Robinson MM, McBryant SJ, Tsukamoto T, Rojas C, Ferraris DV, Hamilton SK, Hansen JC and Curthoys NP. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1, 2, 4-thiadiazol-2-yl)ethyl sulfide (BPTES). The Biochemical journal. 2007; 406:407-414
19. DeLaBarre B, Gross S, Fang C, Gao Y, Jha A, Jiang F, Song JJ, Wei W and Hurov JB. Full-length human glutaminase in complex with an allosteric inhibitor. Biochemistry. 2011; 50:10764-10770
20. Katt WP, Ramachandran S, Erickson JW and Cerione RA. Dibenzophenanthridines as inhibitors of glutaminase C and cancer cell proliferation. Molecular cancer therapeutics. 2012; 11:1269-1278
21. Lee SY, Jeon HM, Ju MK, Jeong EK, Kim CH, Park HG, Han SI and Kang HS. Dlx-2 and glutaminase upregulate epithelialmesenchymal transition and glycolytic switch. Oncotarget. 2016; 7:7925-7939. doi: 10.18632/oncotarget.687
22. Simpson NE, Tryndyak VP, Pogribna M, Beland FA and Pogribny IP. Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype. Epigenetics. 2012; 7:1413-1420
23. Yoon S and Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth factors. 2006; 24:21-44
24. Moody TW, Berna MJ, Mantey S, Sancho V, Ridnour L, Wink DA, Chan D, Giaccone G and Jensen RT. Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. European journal of pharmacology. 2010; 637:38-45
25. Levine B and Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008; 132:27-42
26. Mizushima N, Yoshimori T and Ohsumi Y. The role of Atg proteins in autophagosome formation. Annual review of cell and developmental biology. 2011; 27:107-132
27. Zhi X and Zhong Q. Autophagy in cancer. F1000prime reports. 2015; 7:18
28. McAfee Q, Zhang Z, Samanta A, Levi SM, Ma XH, Piao S, Lynch JP, Uehara T, Sepulveda AR, Davis LE, Winkler JD and Amaravadi RK. Autophagy inhibitor Lys05 has singleagent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:8253-8258